| Quarterly Financials | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 188 | 208 | 190 | 189 | 192 | 237 | 213 | 215 | 251 | 267 | 259 | 223 | 275 | 286 | 270 | 243 | 289 | 327 | 308 | 277 | 350 | 360 | 333 | 309 | 395 | 461 | 420 | 398 | 461 | 504 | 488 | 562 | 717 | 744 | 726 | 711 | 775 | 793 | 801 |
| Expenses | 109 | 125 | 112 | 135 | 114 | 152 | 128 | 141 | 162 | 164 | 159 | 153 | 170 | 175 | 190 | 171 | 189 | 205 | 203 | 184 | 223 | 220 | 210 | 209 | 269 | 309 | 286 | 284 | 297 | 324 | 311 | 403 | 470 | 477 | 477 | 453 | 496 | 504 | 543 |
| EBITDA | 79 | 83 | 78 | 54 | 78 | 86 | 85 | 75 | 88 | 103 | 100 | 70 | 105 | 111 | 81 | 72 | 100 | 122 | 105 | 93 | 127 | 141 | 123 | 100 | 125 | 151 | 134 | 114 | 164 | 180 | 177 | 160 | 248 | 267 | 249 | 258 | 279 | 289 | 258 |
| Operating Profit % | 40 % | 37 % | 39 % | 27 % | 39 % | 34 % | 38 % | 32 % | 34 % | 37 % | 36 % | 28 % | 38 % | 38 % | 28 % | 30 % | 34 % | 37 % | 33 % | 33 % | 35 % | 38 % | 36 % | 31 % | 31 % | 32 % | 32 % | 28 % | 35 % | 35 % | 36 % | 26 % | 34 % | 35 % | 34 % | 36 % | 36 % | 36 % | 32 % |
| Depreciation | 5 | 5 | 6 | 7 | 5 | 5 | 7 | 9 | 7 | 8 | 10 | 11 | 12 | 12 | 13 | 14 | 10 | 11 | 11 | 12 | 15 | 15 | 17 | 18 | 23 | 29 | 30 | 35 | 41 | 42 | 46 | 54 | 76 | 81 | 81 | 77 | 71 | 69 | 70 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 8 | 7 | 6 | 5 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 3 | 9 | 17 | 16 | 18 | 33 | 60 | 60 | 57 | 54 | 49 | 50 | 49 |
| Profit Before Tax | 73 | 78 | 72 | 48 | 74 | 99 | 77 | 62 | 78 | 92 | 89 | 58 | 95 | 103 | 72 | 62 | 95 | 116 | 99 | 85 | 117 | 131 | 109 | 85 | 101 | 121 | 107 | 76 | 113 | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 | 145 |
| Tax | 11 | 8 | 4 | 1 | 3 | 6 | 3 | 6 | 6 | 7 | 9 | 4 | 11 | 10 | 9 | 5 | 6 | 8 | 9 | 17 | 10 | 12 | 8 | 5 | 8 | 2 | 6 | 14 | 19 | 4 | 14 | -3 | 26 | 33 | 29 | 27 | 36 | 38 | 37 |
| Net Profit | 63 | 69 | 68 | 47 | 71 | 93 | 75 | 56 | 72 | 86 | 80 | 54 | 84 | 93 | 64 | 56 | 89 | 108 | 90 | 68 | 107 | 118 | 101 | 80 | 93 | 119 | 100 | 62 | 94 | 122 | 102 | 80 | 90 | 96 | 87 | 102 | 125 | 135 | 109 |
| EPS in ₹ | 45.64 | 5.02 | 4.95 | 3.43 | 5.15 | 6.75 | 5.43 | 4.06 | 5.18 | 6.20 | 5.83 | 3.93 | 6.11 | 6.74 | 4.62 | 4.13 | 6.56 | 7.93 | 6.64 | 5.03 | 7.86 | 8.71 | 7.41 | 5.91 | 6.96 | 8.84 | 7.49 | 4.81 | 6.97 | 9.08 | 7.55 | 5.22 | 6.11 | 6.73 | 6.16 | 6.90 | 8.66 | 8.82 | 7.32 |
Eris Lifesciences
Eris Lifesciences
1,414.40
-96.00
(-6.36%)
Market Cap
19,266.52 Cr
PE Ratio
46.62
Volume
2,38,365.00
Day High - Low
1,511.00 - 1,389.90
52W High-Low
1,910.00 - 1,097.20
Q3 Quarterly Results are out. Check out the updated financials1 day ago
Show All
Key Fundamentals
Market Cap
19,266.52 Cr
EPS
25.85
PE Ratio
46.62
PB Ratio
5.96
Book Value
230.57
EBITDA
1,035.60
Dividend Yield
0.48 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
11.45
Debt to Equity
0.97
Analyst Rating and Forecast
- By Refinitiv from10 analysts
Actual
Company News
View All News
Eris Lifesciences reported consolidated revenue of ₹807.45 crore for Q3 FY26, up 11.00% YoY. Net profit reached ₹108.83 crore with exceptional items impacting results due to new labour codes.
Eris Lifesciences has scheduled its board meeting for February 13, 2026, to consider and approve Q3FY26 unaudited financial results. Trading window remains closed until 48 hours post-declaration.
Eris Lifesciences Postal Ballot Results Declared
Dec 26, 2025
Dec 26, 2025Eris Lifesciences announces successful completion of postal ballot voting on December 24, 2025, with all four resolutions passed by shareholders with requisite majority through remote e-voting process.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,697.50 | #1 4,07,287.11 | 37.56 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 52.49 | |
6,168.50 | 1,63,754.29 | 66.27 | 9,712.00 | 18.67 | 2,191 | -1.02 | 48.87 | |
4,078.00 | 1,38,018.05 | 64.55 | 11,539.40 | 6.99 | 1,911 | 30.46 | 59.36 | |
1,331.50 | 1,07,554.81 | 23.69 | 28,409.50 | 7.12 | 5,291 | -57.18 | 35.86 | |
1,268.10 | 1,05,839.48 | 19.26 | 33,741.20 | 16.73 | 5,725 | -15.28 | 58.24 | |
2,199.30 | 1,00,463.76 | 23.23 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 56.93 | |
904.70 | 91,033.99 | #1 18.43 | 23,511.00 | 18.55 | 4,615 | -0.32 | 51.32 | |
2,060.50 | 85,058.49 | 47.59 | 12,744.20 | #1 20.90 | 2,007 | 7.65 | 42.02 | |
1,145.60 | 66,536.63 | 19.29 | 32,345.60 | 9.43 | 3,484 | 7.59 | 45.13 | |
5,402.50 | 64,594.99 | 29.06 | 13,458.30 | 3.70 | 2,216 | 10.98 | 36.02 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
43.24 %
Net Income Growth
-5.64 %
Cash Flow Change
119.13 %
ROE
-7.06 %
ROCE
11.27 %
EBITDA Margin (Avg.)
3.46 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,041 | 7,033 |
| Fixed Assets | 65 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,307 |
| Current Assets | 237 | 216 | 299 | 582 | 480 | 467 | 627 | 765 | 2,302 | 1,223 |
| Capital Work in Progress | 0 | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 |
| Investments | 144 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 |
| Other Assets | 190 | 192 | 324 | 435 | 595 | 685 | 807 | 1,041 | 2,686 | 1,593 |
| Total Liabilities | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,041 | 7,033 |
| Current Liabilities | 71 | 76 | 226 | 306 | 165 | 167 | 200 | 443 | 2,532 | 1,381 |
| Non Current Liabilities | 25 | 60 | 349 | 79 | 91 | 91 | 164 | 1,003 | 1,286 | 2,380 |
| Total Equity | 302 | 591 | 886 | 1,169 | 1,296 | 1,576 | 1,908 | 2,221 | 3,222 | 3,272 |
| Reserve & Surplus | 302 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,894 | 2,182 | 2,573 | 2,841 |
| Share Capital | 0 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | 5 | 38 | 106 |
| Investing Activities | -92 | -44 | -185 | -590 | -5 | 123 | -323 | -320 | -975 | -1,828 | -78 |
| Operating Activities | 90 | 132 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 | 1,065 |
| Financing Activities | 1 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1,380 | -881 |
Share Holding
| % Holding | Jan 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
| Promoter | 55.55 % | 54.13 % | 52.69 % | 52.68 % | 52.66 % | 52.66 % | 52.30 % | 52.29 % | 52.70 % | 52.86 % | 52.86 % | 54.91 % | 54.90 % | 54.90 % | 54.88 % | 54.87 % | 54.86 % | 54.85 % | 54.83 % | 54.85 % | 54.85 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 13.20 % | 0.00 % | 14.27 % | 14.59 % | 8.01 % | 8.35 % | 8.43 % | 8.40 % | 7.21 % | 6.85 % |
| DIIs | 10.52 % | 9.25 % | 9.66 % | 9.57 % | 9.99 % | 10.11 % | 10.36 % | 10.38 % | 9.94 % | 10.02 % | 10.28 % | 14.53 % | 13.86 % | 15.63 % | 16.23 % | 18.64 % | 18.06 % | 18.07 % | 18.17 % | 19.36 % | 20.32 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 22.42 % | 23.28 % | 23.23 % | 23.29 % | 23.19 % | 23.14 % | 21.34 % | 21.27 % | 21.45 % | 21.66 % | 22.07 % | 15.47 % | 15.67 % | 14.24 % | 13.53 % | 10.51 % | 9.29 % | 9.16 % | 9.12 % | 9.12 % | 8.51 % |
| Others | 11.51 % | 13.34 % | 14.42 % | 14.46 % | 14.16 % | 14.09 % | 16.01 % | 16.07 % | 15.90 % | 15.46 % | 14.79 % | 1.90 % | 15.57 % | 0.95 % | 0.77 % | 7.96 % | 9.43 % | 9.49 % | 9.47 % | 9.45 % | 9.48 % |
| No of Share Holders | 29,195 | 41,470 | 46,477 | 49,833 | 54,223 | 57,061 | 51,639 | 48,055 | 46,746 | 45,931 | 44,169 | 42,245 | 46,496 | 51,753 | 44,176 | 46,346 | 53,314 | 50,087 | 52,225 | 59,438 | 54,713 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 2.87 | 5.5 | 6.01 | 7.35 | 0.00 | 7.35 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.47 | 0.8 | 1.05 | 0.87 | 0.00 | 0.52 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 06 Aug 2021 |  Dividend | ₹ 6.01 /share | 05 Aug 2021 | 742.15 | 747.90 |
| 16 Aug 2022 | Dividend | ₹ 7.35 /share | 11 Aug 2022 | 696.65 | 695.05 |
| 25 Sept 2024 |  Annual General Meeting | NA | 25 Sept 2024 | 1,454.10 | 1,311.75 |
| 25 Oct 2024 |  Quarterly Result Announcement | NA | 25 Oct 2024 | 1,329.15 | 1,282.30 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,157.90 | 1,248.00 |
| 13 Feb 2025 | Dividend | ₹ 7.35 /share | 13 Feb 2025 | 1,460.10 | 1,301.85 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 1,402.05 | 1,465.15 |
| 25 Jul 2025 | Annual General Meeting | NA | 25 Jul 2025 | 1,679.60 | 1,780.65 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 1,791.20 | 1,801.10 |
| 12 Nov 2025 | Quarterly Result Announcement | NA | 12 Nov 2025 | 1,599.60 | 1,595.20 |
| 13 Feb 2026 | Quarterly Result Announcement | NA | 13 Feb 2026 | 1,412.95 | 1,511.05 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Investor Presentation1 day ago
1 day agoUnaudited Financial Results For The Quarter And Nine Months Ended December 31 20251 day ago
1 day agoBoard Meeting Outcome for Outcome Of Board Meeting1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
8 days agoBoard Meeting Intimation for Approval Of Financial Results8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-AllotmentJan 16, 2026
Jan 16, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 12, 2026
Jan 12, 2026Closure of Trading WindowDec 29, 2025
Dec 29, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportDec 26, 2025
Dec 26, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotDec 26, 2025
Dec 26, 2025Announcement under Regulation 30 (LODR)-CessationDec 18, 2025
Dec 18, 2025Second Corrigendum To The Notice Of Postal Ballot Dated November 24 2025Dec 17, 2025
Dec 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 15, 2025
Dec 15, 2025 Clarification With Respect To Increase In VolumeDec 10, 2025
Dec 10, 2025Clarification sought from Eris Lifesciences LtdDec 10, 2025
Dec 10, 2025Corrigendum To The Notice Of Postal Ballot Dated November 24 2025Dec 05, 2025
Dec 05, 2025Corporate PresentationDec 03, 2025
Dec 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 26, 2025
Nov 26, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 24, 2025
Nov 24, 2025Announcement under Regulation 30 (LODR)-AcquisitionNov 24, 2025
Nov 24, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesNov 24, 2025
Nov 24, 2025Board Meeting Outcome for Meeting Dated November 24 2025Nov 24, 2025
Nov 24, 2025Board Meeting Intimation for Issuance Of Equity Shares Of The Company By Way Of A Preferential IssueNov 19, 2025
Nov 19, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSNov 17, 2025
Nov 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 12, 2025
Nov 12, 2025Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 12, 2025
Nov 12, 2025Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2025
Nov 06, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 06, 2025
Nov 06, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 11, 2025
Sep 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 30, 2025
Aug 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 25, 2025
Aug 25, 2025Announcement Under Regulation 30 (LODR) - Receipt Of Show Cause NoticeAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Resignation of Statutory AuditorsAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 05, 2025
Aug 05, 2025Unaudited Financial Results For The Quarter Ended June 30 2025Aug 05, 2025
Aug 05, 2025Board Meeting Outcome for The Board Meeting Held On August 05 2025Aug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 31, 2025
Jul 31, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 60.69
ATR(14)
Volatile 47.29
STOCH(9,6)
Overbought 85.90
STOCH RSI(14)
Overbought 97.59
MACD(12,26)
Bullish 17.94
ADX(14)
Weak Trend 20.25
UO(9)
Bearish 61.76
ROC(12)
Uptrend And Accelerating 11.81
WillR(14)
Overbought -8.17
About Eris Lifesciences
Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands...more
Listing Date
29 Jun, 2017(8 Years,
17 days)
Website
Chairperson NameAmit Indubhushan Bakshi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
